Europe Cancer Therapy Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Europe Cancer Therapy Market Trends and Insights

Precision-Oncology Drug Approvals Surge Post-EMA Reforms

Streamlined adaptive-licensing pathways now close EMA review cycles in roughly 12 months, enabling 28 oncology approvals in 2024 and sustaining double-digit growth in 1H 2025. First-in-class agents for KRAS G12C, FGFR, and HER2-low indications cleared evaluation within 10 months, and linked companion diagnostics were reimbursed under conditional-coverage rules in Germany and France, fostering rapid clinical adoption. Joint HTA assessments published by EUnetHTA are supporting smaller markets without oncology units, thereby helping to reduce access disparities. As real-world evidence matures, pricing tiers are increasingly tied to post-launch outcomes, anchoring durable growth in the European cancer therapy market.

Biosimilar Oncology Uptake Lowering Therapy Costs

Volume penetration for trastuzumab, bevacizumab, and rituximab biosimilars reached 41% across Germany, the UK, and the Netherlands by December 2024, generating cumulative system savings of EUR 56 billion. France’s January 2025 substitution mandate compels pharmacists to dispense the least-cost biologic, an initiative forecast to save EUR 1.2 billion annually by 2027. Spain’s gain-sharing model splits procurement savings with providers to fund CAR-T and radioligand access. The European Commission aims for 60% biosimilar penetration by 2030, adding further downward pressure on mature segments while liberating budgets for innovative classes.

Genomic Screening Roll-Outs in EU27 Cancer Plans

National genomic-medicine strategies in France and Germany mandate broad tumor profiling, scaling to 235,000 annual assays by 2027. Nordic registries integrate genomic data into national quality databases, providing real-world endpoints to support adaptive reimbursement. Early pilot programs in Poland and the Czech Republic are training pathologists and bioinformaticians, extending the benefits of precision oncology to Central Europe. As testing volumes rise, companion diagnostic throughput will improve treatment matching and accelerate uptake of targeted regimens across the Europe cancer therapy market.

Venture-Capital Boom for Radioligand Start-Ups

Investors injected EUR 622 million into 11 European radioligand companies over 2024-2025. ITM’s EUR 188 million Series C is scaling actinium-225 and lead-212 supply, while PanTera’s EUR 134 million Series B advances thorium-227 programs. Sanofi and Orano Med earmarked EUR 300 million to build a lead-212 facility, and EMA draft guidance on alpha-emitter dosing signals regulatory tailwinds. These funds are accelerating pipeline readouts and facility build-outs, positioning radioligands as a high-growth pillar of the Europe cancer therapy industry.

Divergent HTA Reimbursement Timelines Across EU-5

The W.A.I.T. (Waiting to Access Innovative Therapies) indicator survey shows an average 531-day lag between EMA approval and patient availability across the five largest markets, reflecting heterogeneous evidence and pricing requirements. While the 2025 Joint Clinical Assessment regulation aims to align methodologies, transitional frictions may widen gaps as national agencies recalibrate their value frameworks. Germany’s AMNOG process releases provisional payments 90 days after EMA approval, whereas Italy typically takes 18-24 months before formulary listing. France offers early Autorisation Temporaire d’Utilisation use, yet budget constraints hold full reimbursement until HTA completion. The UK Cancer Drugs Fund now conditions access on 12-month outcomes, extending timelines to 11 months. Spain’s autonomous regions create additional intra-country variation, adding approximately EUR 12 million in administrative costs per launch and fragmenting strategies for companies in the Europe cancer therapy market.

Hospital Capacity Gap for Nuclear-Medicine Therapies

Southern and Central-Eastern Europe face shortages of shielded suites and trained radiopharmacists required for alpha-emitter treatments. Workforce deficits in radiation oncology, particularly in Hungary and Romania, extend wait times to twice the EU median. Although the European Commission’s Cancer Mission earmarked EUR 47 million for workforce programs, incremental staffing will take years to materialize, capping radioligand uptake in underserved regions.

Segment Analysis

By Therapy Type: Targeted Agents Erode Chemotherapy Dominance

Chemotherapy retained a 41.92% share of the Europe cancer therapy market size in 2025, reflecting its entrenched role in combination regimens. Yet targeted therapy is forecast to post a 6.14% CAGR, propelled by HER2-low breast cancer approvals and next-generation EGFR inhibitors that extend progression-free intervals. A maturing immunotherapy backbone is increasingly paired with precision inhibitors, enabling deeper responses across various tumor types and elevating biomarker testing rates.  

Increasing clinical trial density underscores a strategic emphasis on tumor-agnostic indications, with basket study designs compressing development cycles. Biosimilar erosion in traditional cytotoxics accelerates revenue migration toward precision platforms, prompting legacy manufacturers to replenish pipelines via licensing or bolt-on acquisitions. The shift also reorients hospital formularies toward outpatient administration, reinforcing payer preference for cost-effective, biomarker-guided protocols.

Note: Segment shares of all individual segments available upon report purchase

By Cancer Type: Lung Cancer Therapies Outpace Breast Cancer Growth

Breast cancer dominated the Europe cancer therapy market, accounting for a 25.12% share in 2025, driven by established screening programs and well-established treatment algorithms. However, lung cancer is slated for the fastest 6.77% CAGR through 2031 as first-line immunotherapy combinations and exon-20 insertion inhibitors unlock previously refractory segments.  

Tighter environmental policies on smoking and air-quality metrics may gradually reduce incidence. Yet the rapid adoption of molecular diagnostics broadens the eligible patient pool for targeted regimens in the near term. Pharmaceutical companies thus prioritize portfolio depth across genomic subsets, balancing blockbuster volume in hormone-positive breast cancer with high-growth revenue in niche lung-cancer mutations.

By Drug Class: Antibody-Drug Conjugates Lead Innovation Wave

PD-1/PD-L1 inhibitors captured 31.55% of 2025 revenue, cementing immune-checkpoint blockade as a multimodal backbone. Antibody-drug conjugates now lead the growth league with a 7.05% CAGR, reflecting advances in linker-payload technology that widen therapeutic windows. Enhanced potency has spurred label expansion into earlier lines, while competitive differentiation revolves around site-specific conjugation and bystander-kill payloads.  

Meanwhile, tyrosine kinase inhibitors are transitioning to fourth-generation agents that overcome solvent-front mutations, and CDK4/6 inhibitors are moving into adjuvant settings. Pipeline clustering amplifies deal-making for proprietary conjugation platforms, with out-licensing models offering capital-efficient entry for mid-cap firms seeking to gain exposure to the rapidly scaling ADC arena.

Note: Segment shares of all individual segments available upon report purchase

By Mode of Administration: Subcutaneous Formulations Gain Traction

Intravenous infusion maintained a 68.20% share in 2025; however, subcutaneous formulations are projected to expand at a 6.99% CAGR through 2031 as health systems champion home-based care. On-body injectors for monoclonal antibodies reduce chair time and free oncology-day-unit capacity, dovetailing with workforce-optimization targets.  

Oral oncology pipelines also flourish, supported by adherence-monitoring apps and digital pill dispensers that mitigate compliance risks. Manufacturers investing in formulation science and device partnerships gain first-mover advantage, while payer scrutiny intensifies on intravenous price premiums absent clear clinical benefit over patient-centric routes.

By End User: Specialty Clinics Capture Ambulatory Shift

Hospitals accounted for 60.50% of the European cancer therapy market in 2025, anchored by CAR-T and multi-day chemo protocols that require intensive monitoring. Specialty oncology clinics are advancing at 6.87% CAGR as payers incentivize lower-cost ambulatory settings that cut per-treatment expenses by up to 25%. Germany’s office-based network now delivers 62% of systemic cancer care, and France added 47 infusion chairs across regional centers during 2024-2025. Home-care programs, though accounting for only 4.7% share, are the fastest-growing end-user segment at a 7.2% CAGR, enabled by digital monitoring and subcutaneous formulations.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

Germany generated 28.05% of Europe cancer therapy market revenue in 2025, underpinned by growing annual pharmaceutical R&D outlays and dense Phase III trial networks in oncology centers of excellence. Early-benefit assessments facilitate rapid reimbursement for breakthrough therapies, encouraging manufacturers to prioritize German launches.  

France, projected to log an 8.45% CAGR through 2031, accelerates through national genomic-screening rollouts and expedited HTA pathways, which have cut average review times by 15% since 2023. Coupled with centralized hospital purchasing, the reforms streamline market entry for targeted agents, enlarging addressable patient pools in both urban and regional cancer institutes.  

The United Kingdom maintains a sizable demand despite post-Brexit realignment, as the Medicines and Healthcare products Regulatory Agency (MHRA) mutual-recognition initiative preserves access to EMA dossiers. Italy and Spain advance through biosimilar uptake and increased oncology spending allocation, while Nordic countries leverage digital registries to optimize precision medicine deployment. Central and Eastern European markets, though smaller, record double-digit nominal growth supported by EU Cohesion Fund investments in radiotherapy infrastructure.